References
Acar JF, Goldstein FW, Duval J (1983) Use of rifampicin for the treatment of serious staphylococcal and gram-negative bacillary infections. Rev Infect Dis 5(Suppl 3):502–506
Hackbarth CJ, Chambers HF, Sande M (1986) Serum bactericidal activity of rifampicin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother 29:611–613
Foldes M, Munro R, Sorrell TC (1983) In-vitro effects of vancomycin, rifampicin, fusidic acid, alone and in combination against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 11:21–26
Wichelhaus TA, Hunfeld KP, Boddinghaus B, Kraiczy P, Volker S (2001) Rapid molecular typing of methicillin-resistant Staphylococcus aureus by PCR-RFLP. Infect Control Hosp Epidemiol 22:294–298
Norazah A, Lim VK, Koh YT, et al (2002) Molecular fingerprinting of fusidic acid- and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals. J Med Microbiol 51:1113–1116
Barry MF (2000) Rifamycins. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. 5th ed. Vol 1. Churchill Livingstone, New York, pp 348–356
Kapusnik JE, Parenti F, Sande M (1984) The use of rifampicin in staphylococcal infection—a review. J Antimicrob Chemother 13:61–66
Acknowledgements
We thank the Pharmacy Department and Infection Control Unit for their assistance with data collection.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ju, O., Woolley, M. & Gordon, D. Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin–rifampicin combination therapy in an intensive care unit. Eur J Clin Microbiol Infect Dis 25, 61–62 (2006). https://doi.org/10.1007/s10096-005-0063-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-005-0063-1